First Tracks Biotherapeutics, Inc. TRAX Stock Forecast
AI-powered price prediction and analysis for First Tracks Biotherapeutics, Inc. · Total · absolute moveSwitch to Alpha
See TRAX's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc. (TRAX) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry.
Latest News
Where TRAX sits on the market map
Pharmaceutical Preparations Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| TRAX First Tracks Biotherapeutics, Inc. | $1.91B | – | |
| LLY Eli Lilly & Co | $1.28T | 44.3x | |
| JNJ Johnson & Johnson | $655.56B | 41.4x | |
| ABBV Abbvie Inc. | $509.35B | 44.1x | |
| MRK Merck & Co., Inc. | $362.53B | 151.5x | |
| NVS Novartis Ag | $308.99B | 9.7x | |
| AZN Astrazeneca Plc | $289.62B | 13.5x | |
| ABT Abbott Laboratories | $197.53B | 40.1x | |
| NVO Novo Nordisk A S | $179.09B | 3.0x | |
| PFE Pfizer Inc | $170.31B | 37.8x | |
| VRTX Vertex Pharmaceuticals Inc / … | $137.50B | 34.9x | |
| BMY Bristol Myers Squibb Co | $129.04B | 14.0x | |
| SNY Sanofi | $115.65B | – | |
| GSK Gsk Plc | $101.70B | 5.6x | |
| REGN Regeneron Pharmaceuticals, Inc. | $92.96B | 20.0x | |
| TAK Takeda Pharmaceutical Co Ltd | $66.19B | 6.4x | |
| TEVA Teva Pharmaceutical Industries Ltd | $48.69B | 40.2x | |
| ONC Beone Medicines Ltd. | $44.02B | 1075.7x | |
| ZTS Zoetis Inc. | $33.93B | 14.0x | |
| GMAB Genmab A/S | $33.93B | 2.1x | |
| RPRX Royalty Pharma Plc | $28.94B | 47.3x | |
| ROIV Roivant Sciences Ltd. | $26.45B | – | |
| UTHR United Therapeutics Corp | $24.26B | 21.4x | |
| INSM Insmed Inc | $23.86B | – | |
| VTRS Viatris Inc | $21.79B | – | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.98B | 7.4x | |
| ASND Ascendis Pharma A/S | $16.64B | – | |
| JAZZ Jazz Pharmaceuticals Plc | $14.76B | 75.0x | |
| BBIO Bridgebio Pharma, Inc. | $14.47B | – | |
| RDY Dr Reddys Laboratories Ltd | $12.13B | 16.0x | |
| ELAN Elanco Animal Health Inc | $11.83B | – | |
| SMMT Summit Therapeutics Inc. | $11.32B | – | |
| BMRN Biomarin Pharmaceutical Inc | $10.86B | 561.2x | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.24B | – | |
| TGTX Tg Therapeutics, Inc. | $9.20B | 21.9x | |
| PTGX Protagonist Therapeutics, Inc | $8.75B | 171.2x | |
| SYRE Spyre Therapeutics, Inc. | $8.52B | – | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.12B | – | |
| CORT Corcept Therapeutics Inc | $7.74B | 42.9x | |
| CYTK Cytokinetics Inc | $7.72B | – | |
| ALKS Alkermes Plc. | $7.47B | 43.2x | |
| PRAX Praxis Precision Medicines, Inc. | $7.33B | – | |
| ABVX Abivax S.A. | $7.32B | – | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.23B | – | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $6.94B | 81.8x | |
| AXSM Axsome Therapeutics, Inc. | $6.80B | – | |
| IONS Ionis Pharmaceuticals Inc | $6.45B | – | |
| ORKA Oruka Therapeutics, Inc. | $6.36B | – | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.21B | 58.9x | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.07B | – | |
| LGND Ligand Pharmaceuticals Inc | $5.98B | 114.1x | |
| BLTE Belite Bio, Inc | $5.63B | – | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | – | |
| PTCT Ptc Therapeutics, Inc. | $5.49B | – | |
| MANE Veradermics, Inc | $5.37B | – | |
| COGT Cogent Biosciences, Inc. | $5.13B | – | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.64B | – | |
| ERAS Erasca, Inc. | $4.64B | – | |
| TVTX Travere Therapeutics, Inc. | $4.37B | – | |
| EWTX Edgewise Therapeutics, Inc. | $4.22B | 4.6x |
FAQ
Is First Tracks Biotherapeutics, Inc. a good stock to buy?
Our AI analyzes First Tracks Biotherapeutics, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are First Tracks Biotherapeutics, Inc. predictions?
A per-ticker accuracy statistic for TRAX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
First Tracks Biotherapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of First Tracks Biotherapeutics, Inc.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.